All News
Treatment Options for Still's Disease
Are you treating “systemic” or “articular” (arthritis) Still’s disease? Most Still’s patients have a dominance of one or the other. With certainty, the right therapy for the right symptoms can be chosen. What about patients who have an incomplete or no response, or who become unresponsive to a drug that once worked well?
Read ArticleEarly, Aggressive and Seropositive (7.22.2022)
Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.
Read ArticleTreating Enthesitis in Psoriatic Arthritis Patients
A large prospective psoriatic arthritis (PsA) study examined the enthesitis outcomes when PsA patients received conventional (cDMARDs) or targeted disease-modifying antirheumatic drugs (tDMARDs) and showed an overall 86% response rates, regardless of the medication used.
Read ArticleLinks:
Links:
Links:
Links:
David Liew drdavidliew ( View Tweet)
Links:
Links:
Links:
The Still’s Continua The concept of a “Still’s disease continuum” that encompasses both sJIA and AOSD is based on the many common clinical, genetic and laboratory features shared by both sJIA and AOSD. https://t.co/XvtzGBX4MS https://t.co/WJC8U9JNXO
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links: